Abstract
The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor that acts as an environmental sensor by binding to a variety of xenobiotics. AHR activation serves to combat xenotoxic stress by inducing metabolic enzyme expression in the liver. The hepatitis B virus X-associated protein (XAP2) is a component of the cytosolic AHR complex and modulates AHR transcriptional properties in vitro and in cell culture and yeast systems. Expression of XAP2 is low in liver compared with other nonhepatic tissues and the AHR exhibits high ligand-induced transcriptional activity. Because XAP2 has been demonstrated to repress AHR activity, we hypothesized that XAP2 may be limiting in liver and that increasing XAP2 levels would attenuate AHR transcriptional activity. To this end, transgenic mice were generated that exhibit hepatocyte-specific elevation in XAP2 expression. Transgenic XAP2 expression was restricted to liver, and its ability to complex with the AHR was verified. Gene expression experiments were performed by inducing AHR transcriptional activity with β-naphthoflavone via intraperitoneal injection, and mRNA quantification was done by real-time polymerase chain reaction. Wild-type and transgenic animals showed little difference in constitutive or ligand-induced CYP1A1; CYP1A2; UDP glucuronosyltransferase 1A2; NAD(P)H dehydrogenase, quinone 1; constitutive androstane receptor; or nuclear factor erythroid 2-related factor 2 mRNA expression. Sucrose density fractionation and AHR immunoprecipitation experiments found little or no stoichiometric increase in bound XAP2 to the AHR between genotypes. Gene array studies were performed to identify novel XAP2-regulated targets. Taken together, this work shows that despite the relatively low level of XAP2 in liver, it is not a limiting component in AHR regulation.
Footnotes
-
This work was supported by National Institute of Environmental Health Sciences, National Institutes of Health grants ES04869 and ES007799, and The Penn State Transgenic Mouse Facility and National Center for Research Resources Facilities Improvement grant 1 CO6 RR14520 (OSP 69310).
-
Portions of this work were presented at the 4th Annual Merck Graduate Student Drug Metabolism Symposium (2006).
-
ABBREVIATIONS: AHR, aryl hydrocarbon receptor; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; HSP90, 90-kDa heat shock protein; XAP2, hepatitis B virus X-associated protein 2; PCR, polymerase chain reaction; QRT-PCR, quantitative real-time polymerase chain reaction; β-NF, β-naphthoflavone; FABPL, liver fatty acid binding protein; ACOX1, acyl-coenzyme A oxidase 1; PBS, phosphate-buffered saline; NQO1, NAD(P)H dehydrogenase, quinone 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UGT1A2, UDP-glucuronosyltransferase 1A2; CAR, constitutive androstane receptor; NRF2, nuclear factor erythroid 2-related factor 2; PPAR, peroxisome proliferator-activated receptor; Wy-14,643, pirinixic acid; 4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thioacetic acid; MENG, 25 mM 3-(N-morpholino)propanesulfonic acid, 2 mM EDTA, 0.02% NaN3, and 10% glycerol, pH 7.5; PVDF, polyvinylidene difluoride; TSDS-PAGE, Tricine SDS-polyacrylamide gel electrophoresis; RXR, retinoid X receptor; NP-40, Nonidet P-40; PER/ARNT/SIM, periodicity/aryl hydrocarbon receptor nuclear translocator/simple-minded.
- Received July 25, 2006.
- Accepted September 19, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|